Bayer Aktiengesellschaft (BAYN) Earnings Call Transcript & Summary

November 3, 2026

Deutsche Boerse Xetra DE Health Care Pharmaceuticals earnings 69 min

Earnings Call Speaker Segments

Jana Ackermann

executive
#1

Good afternoon, everyone, and good morning as well. Thank you for joining the conference call where we'll be covering Bayer's results for the third quarter of 2026. My name is Jana Ackermann, and I'm delighted to greet all of you today in my new role as Bayer's Head of Investor Relations. We appreciate that you've taken the time to be with us on this call. I'm eager to engage with you and to collaborate closely with the investor community in the time ahead. During today's presentation, Bill will give an update on how our business has performed so far this year along with our strategic priorities. Judith will follow by taking you through the main drivers behind our results as well as the outlook. Once the prepared remarks are done, the President of each of our 3 divisions will join them for the Q&A session. Please take note of the cautionary language contained in our safe harbor statement before we start. And with that, I'll hand things over to you, Bill.

William Anderson

executive
#2

Thank you, Jana. It's truly wonderful to have everyone joining us. Hello. So earlier today, we released our results for the third quarter. Nine months into the year, we are on course to meet our commitments, backed by solid operational performance, and in several areas we are actually raising our outlook. Organic sales — that is, currency and portfolio adjusted, which is how we'll describe it throughout today's call — rose 3%. Core EPS stands at EUR 3.97, in line with our guidance, notwithstanding certain effects on the corporate lines. As anticipated, free cash flow comes in at negative EUR 3 billion, driven by litigation-related payments that were already known. Overall, our businesses showed operational resilience along with underlying potential. Cost Science and Consumer Health are delivering according to targets while managing market pressures. Our Pharma business, led by Nubeqa and Kerendia, showed its growth potential. Let's look a bit closer. In Crop Science, the third quarter is invariably our smallest. Year-to-date, this business is expanding roughly 3.5%, with the EBITDA margin at 24.6%. Our seeds and traits business is posting double-digit growth, helped by innovation lift and market share gains, most notably in corn worldwide and soy in the U.S. Our core crop protection business is down for the year because of expected portfolio exits, regulatory impacts and greater generic pressure.

William Anderson

executive
#3

A historic drought in Europe and a strong El Nino made this even worse. Turning to what's ahead, LatAm has kicked off the season strongly, and we believe we're well placed to achieve our 2026 outlook. Pharma keeps up its momentum. So far this year, the business is expanding at 2%, with an EBITDA margin of 26.8%. Nubeqa has risen 60% year-to-date, while Kerendia is up 76% over that same period. And we keep enhancing the product profiles and growth prospects for both brands. Our more recent launches are making good progress too. In Q3, Beyonttra broke into our top 15 pharma products by revenues for the first time. Xarelto and Eylea kept declining as we had anticipated, but a turning point has been reached in pharma's growth trajectory, and we're starting to see the other side. For the full year, we now anticipate sales growth toward the upper end of our guidance range, and given our strong performance year-to-date, we're also raising our margin outlook to 25% to 27%. To underpin the future growth trajectory of our pharma business, in Q3 we announced plans to construct a state-of-the-art production facility in New Albany, Ohio. That facility will support our expanding portfolio in oncology, cardiovascular and renal care, and it will complement our global site network in pharmaceuticals, which we'll keep investing in as appropriate.

William Anderson

executive
#4

Now turning to Consumer Health. So far this year, we're at 2% growth, with an EBITDA margin of 22.9%. Both our dermatology and digestive health segments keep expanding, driven by Bepanthen's contributions across every region and by MiraLAX in the U.S. Allergy and cold stands as the sole category in decline, reflecting a weaker season to this point. Market dynamics remain challenging, especially in North America, yet our focus stays on meeting our 2026 commitments and delivering for the consumers who depend on us. On the whole, we remain confident in the group's 2026 targets. We anticipate that our Pharma business will carry its momentum forward and land above earlier projections, and we are raising our outlook for adjusted EBITDA, free cash flow and net financial debt. On the operational side, Bayer keeps making solid progress, and our attention will remain on strengthening performance 90 days at a time. Let's now turn to our strategic priorities. First up, the pharma pipeline. I touched on Nubeqa's growth momentum. At the recent ESMO Congress, we shared interim results that reinforce this medicine's potential. That analysis demonstrated an impressive 58% reduction in the risk of metastasis or death among prostate cancer patients facing a very high risk of recurrence.

William Anderson

executive
#5

This data leaves us feeling good. Naturally, we had our eyes on things like competitor activity, genericization, and pricing pressure, yet in our view these figures underscore the broader potential that Nubeqa holds. The most significant pipeline development arrived early last week, when we secured the first approval for asundexian in secondary stroke prevention in China, marketed as Sunharbo. With asundexian standing as the first Factor XIa inhibitor approved anywhere in the world, our attention now is on securing further approvals. At this point, I'd like to offer congratulations to the Bayer team that brought asundexian to this stage. The molecule was invented by our scientists in Wuppertal, who have spent more than a decade working on it. Despite a major setback in November 2023, they never lost sight of what asundexian might mean for stroke survivors. They have embraced our operating model along with artificial intelligence, which lets them compress the timeline substantially and bring this medicine to patients a year early. That is an incredible impact. Turning to Crop Science profitability, we keep tackling crop protection pressures via actions within our 5-year framework. During Q3, we consolidated crop protection production activities further and lowered costs, and we will keep watching the market closely and act as needed.

William Anderson

executive
#6

We're also pushing forward with differentiated innovation across seeds and traits, and in Crop Protection too. Last month we brought the new insecticide Plenexos to the Mexican market, and the Vyconic soybean stack moved into the final stage of EU import approval, which puts us one step closer to launching this key blockbuster. On the Roundup litigation, we stay focused on our objective of significant containment, and we're on track. In September, the class settlement between plaintiffs Class Counsel and Monsanto reached the final approval hearing, and the company remains confident in the proposed class settlement. We appreciate that it's getting a thorough review, and we await the judge's ruling. Why does this matter? As we've said before, the path to resolving mass litigation in the U.S. almost always involves a settlement, and we reached a deal with plaintiffs Class Council. Together with the Supreme Court's June ruling, the class settlement offers the company the best path to significant containment. That's what we committed to and that's what we aim to deliver. Now as we move toward that goal, there will still be a much smaller number of individual cases pending against the company. One case was just decided in the company's favor. We take that as a strong sign that our containment work is advancing.

William Anderson

executive
#7

The Aretino case from last week mattered a great deal, since it became the initial matter to reach trial following the Supreme Court 72 ruling that invalidated the failure to warrant legal theory. In that particular case, the plaintiffs were required to put forward a legal argument grounded in design defect along with negligence claims. And the reality that all 12 juries sided with the company ought to be instructive for anyone looking to bring claims through the court system. We will keep handling cases in a manner that serves the company's best interests, and we are waiting on a significant ruling regarding the settlement. I also want to bring up PCBs, which are different from the glyphosate matters given how multifaceted the claims are. Our legal approach takes that into account, and we will keep defending these matters vigorously or else pursue settlements. We anticipate legal proceedings over the coming quarters and will act in the company's best interest. Turning to what's ahead, our focus is on finishing 2026 strongly and hitting our targets. The ag season is already underway across Latin America. Pharma has solid momentum thanks to existing launch assets and potential new medicines arriving on the market. And Consumer Health will embrace our operating model in order to navigate a softer market and deliver for the year.

William Anderson

executive
#8

And we see a future for Bayer that's genuinely exciting — one where the company is perceived in a way that differs from how it was seen before. Our attention is on lifting revenues, boosting productivity and generating cash via our operating model and through the roll-out of artificial intelligence. We intend to make capital allocation sharper, directing resources toward the areas with the greatest mission impact, while we keep deleveraging. We'll carry on keeping you updated on how we're progressing, and our next chance to do that comes with the full year results in February next year. Now, Judith, over to you. SP1 Thank you, Bill, and hello everyone. Meeting so many of you face to face since the first half year results has been a pleasure. I look forward to keeping those conversations going. Having completed the first 9 months of the year, we're seeing really good momentum and are pleased that we can upgrade our full year group outlook for adjusted EBITDA, free cash flow and net financial debt. Year-to-date, we achieved organic sales growth of 3% and adjusted EBITDA growth of 7% versus last year. Within Q3, Pharmaceuticals drove group performance more than anything else, underpinning organic sales growth of 2% and adjusted EBITDA growth of 7%.

William Anderson

executive
#9

When it comes to reported results for Q3, foreign exchange effects gave us a year-on-year tailwind, adding roughly EUR 250 million to net sales. The main driver there was a weaker euro versus the U.S. dollar, the Brazilian real and the Chinese renminbi. Looking at the year-to-date picture, though, currency effects are still a drag on our results, cutting sales by about EUR 700 million and adjusted EBITDA by around EUR 360 million. For the year to date, core earnings per share came in at EUR 3.97, helped by stronger operational contributions, especially out of Crop Science and Pharma, which were offset by a weaker core financial results and higher core taxes. Within Q3, solid adjusted EBITDA in pharma was a positive contributor to core EPS. That said, we saw softer performance in the other divisions. We also faced pressure from noncash effects in the financial results, mostly from interest-related fair value changes in certain of our employee benefit and pension instruments. Moving on to free cash flow. We posted a negative EUR 3 billion for the first 9 months of the year, driven in large part by EUR 3.7 billion of litigation related payments. That came in slightly better than expected. If you exclude those payments, underlying operational cash flow is running ahead of prior year, thanks to improved trade working capital as well as licensing resolution income.

William Anderson

executive
#10

During Q3, free cash flow came in at negative EUR 300 million, and that figure includes the second payment made into the class settlement fund. Net financial debt, meanwhile, fell to EUR 31.1 billion, which marks a meaningful improvement against both Q3 '25 and Q2 2026. The main factor behind this was the successful closing of the Apollo equity investment, from which we received proceeds of EUR 3 billion. We had announced that transaction back in the second quarter. Let's turn now to a closer look at how our businesses performed. Within Crop Science, disciplined execution of our 5-year framework underpins resilience in a dynamic ag environment. As a general point, the third quarter tends to be a small one for Crop Science, since the Northern Hemisphere season is wrapping up while the southern hemisphere season is just beginning. That means Q3 says little about full year performance, and you can see that here. Total Crop Science sales were down 2%, as growth in seeds and traits partly offset headwinds in Crop Protection. Year-to-date, though, we see growth of 3.6%. The drop in core crop protection is more than compensated for by strong double-digit growth in seeds and traits over the first 9 months. For '26, we expect to outpace the market, helped by market share gains across several key crops.

William Anderson

executive
#11

During the quarter, seeds and traits rose 3%. In Q3, soybeans increased 5%, powered by robust results in Latin America. Sales year-to-date climbed 45%, or 10% when excluding the first quarter licensing resolution income. The increase came from more acres plus better pricing and market share gains in North America after the U.S. dicamba label returned. That puts us in a good position for the entire year, even though growth should slow in the fourth quarter. Corn sales held steady in Q3. Year-to-date, sales rose 4%, helped by price and volume gains across regions. If we adjust for the prior year licensing resolution income, we anticipate underlying corn growth in Q4, led by Latin America. Core Crop Protection fell 6% in Q3 and year-to-date, reflecting added weather and generic pressures together with regulatory and portfolio headwinds. Unfavorable weather in Europe and El Nino-related effects restrained crop protection applications. We've implemented targeted measures to tackle difficult market conditions, which supported volume growth in Latin America during Q3. We anticipate that momentum carrying into Q4. Glyphosate sales dropped 5% in the quarter, mainly because of weather conditions in EMEA, and were down 2% year-to-date. Turning to profitability, adjusted EBITDA came to roughly EUR 100 million in Q3, with margins easing as anticipated.

William Anderson

executive
#12

What really matters here is that our margin for the year to date stayed above last year's level, at 24.6%. That came about through a favorable sales mix, ongoing delivery against our 5-year framework, and the resolution on licensing. Our pharma business kept carrying out its strategic priorities and began a fresh growth cycle. This represents a significant milestone and a turning point worth pausing on, technology. With the second half of the year now underway, we are observing stronger growth momentum. Net sales rose 6% in Q3, which lifted year-to-date sales to EUR 13.4 billion, a 2% increase year-on-year. That puts us in a good position to close 2026 at the upper end of our full-year sales outlook for pharma. Nubeqa sales rose 58% in Q3 to roughly EUR 1 billion, with growth across regions and especially strong performance in the United States. Year-to-date, Nubeqa now stands at EUR 2.6 billion. Kerendia sales climbed 65% in Q3, primarily driven by the United States and China. Year-to-date, Kerendia sales are close to EUR 1 billion. Given this strong performance, we now expect Kerendia to grow by around 60% for the full year. Beyonttra's launch keeps performing ahead of our expectations. In Q3 it has made it into our top 15 pharma products, and we remain focused on driving uptake through 2026 and beyond.

William Anderson

executive
#13

As we anticipated, Xarelto and Eylea fell 31% and 24%, respectively, in Q3, because of exclusivity loss and biosimilar competition. Importantly, the rate of decline is starting to moderate. Over the first 9 months, sales performance tracks our full-year expectations. Eylea 8-milligram kept up solid volume growth, and it now represents 60% of total Eylea sales. Lastly, our base business stayed a strong contributor to pharma results, with 3% growth year-to-date. In Q3, sales rose 5%, fueled by ongoing momentum in radiology and women's health together with a solid rebound of Adalat and Aspirin Cardio in China. Adjusted EBITDA in Q3 climbed 24%, with the EBITDA margin expanding to 27.6%, chiefly on top line growth. This was additionally helped by a lower inventory write-off, a tail-end product divestment and operational efficiency. At the same time, we keep investing in future growth. Year-to-date, the margin stands at 26.8%, which leads to an upgrade of our full-year margin outlook. Moving to Consumer Health. Sales were up 2% over the first 9 months, with growth across all nonseasonal categories. In the third quarter, sales were broadly stable in a market environment that stayed mixed across geographies and categories; in the U.S. in particular, market conditions remained challenging.

William Anderson

executive
#14

Even so, momentum remains solid across several key areas of our portfolio. MiraLAX led Digestive Health to 5% growth, and dermatology rose 3%, mainly on Bepanthen's continued momentum. Year-to-date, both categories also posted solid growth, with dermatology up 5% and digestive up 3%. That shows how we focus resources on the brands, categories and markets offering the best opportunities for sustainable growth. Allergy and cold sales came in softer, reflecting cautious retail inventory build in the United States ahead of the season. Nutritionals also fell in the quarter because of the competitive environment in the U.S. and EMEA. Even so, Nutritionals remain an important contributor to our year-to-date growth, supported by e-commerce and brands such as Elevit. Turning to profitability: the adjusted EBITDA margin was 24% in the third quarter and 22.9% year-to-date, well within our full year guidance corridor. We keep investing behind our brands and innovation to support future growth. Those investments and foreign exchange headwinds weighed on margins, while productivity gains and disciplined cost management provided a partial offset and preserved our ability to invest in our growth priorities. Let's move on to the group outlook. With the strong pharma performance, we now expect adjusted EBITDA for the group between EUR 9.8 billion and EUR 10.3 billion at constant currencies, up from our initial guidance range of EUR 9.6 billion to EUR 10.1 billion.

William Anderson

executive
#15

We’re reaffirming the core EPS guidance range we have now. Core financial results and core taxes should stay inside the modeling ranges, and that includes the noncash effect from Q3. On free cash flow, we keep pulling every cash flow lever we have, and that means profits, working capital and CapEx. We’re lifting the full year outlook by EUR 1 billion, to minus EUR 1.5 million to minus EUR 0.5 billion. The earlier forecast was minus EUR 2.5 million to minus EUR 1.5 billion. Better free cash flow performance is expected to bring lower net financial debt at year-end, and we now expect EUR 28 million to EUR 29 billion at constant currencies. That compares with the prior range of EUR 29 million to EUR 30 billion. Last, on currencies, we’ve refreshed the foreign exchange estimate using September month and spot rates, and it stays rather stable versus our last estimate. I’ll finish with the divisional outlook. In Crop Science, how we performed through the first 9 months keeps us on track to deliver within our full year guidance ranges. Strong seeds and traits performance should offset additional core Crop Protection headwinds.

William Anderson

executive
#16

As we look toward the fourth quarter, we anticipate continued momentum in Latin America. In crop science, the year-on-year comparison is going to be affected by licensing income from the prior year. When it comes to our Pharma business, Q3 represents the beginning of a sustainable return to growth. Given how we're performing right now, we expect to close out 2026 at the upper end of our organic sales growth outlook. We're still committed to investing in our launches and moving our pipeline forward in Q4, and top line growth should provide further support for full year margin expansion. So we're raising our full year outlook for the adjusted EBITDA margin to a range of 25% to 27%, compared with 23% to 25% before. On Consumer Health, the first 9 months of performance back up our full year guidance. Given how the year has developed so far and what we're currently projecting for the fourth quarter, we expect full year growth in the lower half of the guidance range. Market conditions are still mixed, particularly in the United States, and competitive dynamics in Nutritionals along with how the cough cold season develops remain important factors for the fourth quarter. Our focus is unchanged: invest behind our strongest brands and innovation while directing resources toward our most attractive growth opportunities.

William Anderson

executive
#17

As we look forward, naturally, our 2027 outlook will come alongside the full year 2026 results, but I'd like to point out a few trends we're observing. First, Crop Science is up against a more difficult year-on-year comparison, since licensing resolution income won't be there. We're still watching a mixed agricultural backdrop — pressure on primary economics, generic competition and uncertainty around weather — yet we believe underlying demand stays resilient. We'll take appropriate steps as we carry out our 5-year framework. Second, U.S. tariffs on pattern and pharmaceuticals are already factored into this year's guidance. Regarding drug pricing, we keep assessing what U.S. most favorite nation policies could mean for our pricing and launch strategies. Let me close my remarks by restating that we stay firmly focused on our financial priorities: strengthening our balance sheet, improving productivity and cash generation, and building financial flexibility so we can invest into next-generation growth. With that, I'll hand it over to you, Jana, for the Q&A.

Jana Ackermann

executive
#18

Thanks a lot, Judith, and thanks to you, Bill. At this point we'll move into a Q&A session. <<operator_script>> Today's first question is from Richard Vosser at JPMorgan.

Richard Vosser

analyst
#19

Possibly just one question on Crop Science, plus a comment on what you’ve just said, Judith. Thinking about that 5-year framework — I believe that 5-year framework included margin expansion reaching roughly the mid-20s. But could you maybe say a bit about how the shape of that looks in '27? I think at the crop day, there was an idea of some improvement, but not a linear path to some improvement in '27. So just a few more thoughts on '27, and a little more detail around EBITDA margins and perhaps the top line too. And then my second question is on Nubeqa for Pharma. Maybe you could discuss the potential for growth ahead in a bit more detail. You mentioned that <<inaudible>> trial. So maybe your thinking on what impact that has — perhaps a little more on the impact we should expect for XTANDI Generics in '27. And then beyond that, there’s probably a bit of IRA and other things, but bringing it all together, how should we think about growth as Nubeqa going forward.

William Anderson

executive
#20

Okay. Would you like to go, or should Rodrigo take the question about crop margins?

Judith Hartmann

executive
#21

Okay, Rodrigo, perhaps I'll begin and then you can add some detail. Naturally we aren't providing guidance for '27, but Richard, you're right to raise the question of whether we detect any patterns as we move ahead. Something I consider really essential is our commitment to outperform market conditions, and I believe we're demonstrating that this year, and that is also what the team forecasts for the coming year. Keep in mind the licensing income. Of course, you're aware that this year we're seeing something that won't recur next year. And regarding margin, a great deal of effort is underway. I'm certain Rodrigo will have plenty of examples here, everything from consolidating factories to renegotiating contracts, all kinds of initiatives. So the team is maintaining a solid focus on enhancing the margin there.

Rodrigo Santos

executive
#22

Alright, Judith, you covered that really thoroughly. Richard, I'll build on the question you just asked, since you wrapped up with the top line and the margin — using roughly '27 as the anchor, let me go deeper on those 3 elements Judith brought up. First, market conditions. Yes, with El Nino and the geopolitical situation — including what's recently happened in Ukraine and the Black Sea restrictions — we're anticipating a great deal of uncertainty and volatility in the market, plus the farmer economics that were also raised, and even a likely cut in U.S. corn area. So as you've heard from other companies too, market conditions stay challenging for '27. That's element one. Element two, which matters, is what Judith pointed to: the licensing resolution hit Q4 of '25 in corn and Q1 '26 in soybean, and that won't repeat in '27. So on reported sales, you'll see moderation in both top line and margin for that reason. But that leads me to the underlying business, which remains on track with the 5-year framework. Next year, we expect to perform above market.

Rodrigo Santos

executive
#23

Our seeds and traits are still delivering, and we're seeing really strong performance this year. Also in Crop Protection—just to give a few of the examples that were mentioned—we had Plenexos in Mexico next year. We expect the U.S. and Brazil, a very important market. We also expect Stryax to keep expanding in Covestro, again Brazil and the U.S., plus other products we have. So the underlying business, both on the top line and on the margin, we remain on the path toward our midterm ambition that you mentioned. So those 3 elements matter a lot for '27, and we'll give far more detail in February, as Judith mentioned. Thank you for your question. And with that, Stefan.

Stefan Oelrich

executive
#24

Richard, and thanks for asking about Nubeqa. So yes, certainly, we're enthusiastic about the results we're observing and about adding new indications down the road, since we need to determine what the <<inaudible>> tells us regarding the regulatory pathway for it. And then when it comes to the future growth profile, of course, we aren't providing guidance for '27 here or for subsequent years. But I think we can be optimistic, obviously, as we're going to expand our user base. We've stated that at present, we cover about 60%, and we're moving toward covering 80% of all eligible ARI potential patients, which helps us drive our volume share. On XTANDI, we'll have to see. There's certainly a pricing headwind coming. And when you look at the growth, we're not necessarily defending our percentage growth, but our base is increasing so that we continue to see continued growth for Nubeqa, and everything else will inform in more detail at the beginning of next year. Thank you.

Jana Ackermann

executive
#25

Sachin Jain from Bank of America has the second question.

Sachin Jain

analyst
#26

First, a question for Stefan, then one for Bill. Stefan, this is on <<inaudible>>. You mentioned the recent approval in China. The label was strong, and it seemed to permit the product while reflecting safety well. So, should we treat that as a rough proxy for the U.S. label, or can you comment on how those discussions are progressing? And then, with the <<inaudible>> data coming, could you update us on how you're viewing your commercial scenarios depending on their data? Then just one for Bill. Thanks for the commentary on the glyphosate class settlement. Maybe you could also update us on when you expect to hear back on that? Any color you're willing to give on opt-outs, and how comfortable are you with the debate on the future cases, which seem to be a bit of a sticking point in the discussion.

Stefan Oelrich

executive
#27

Yes. Sachin, thank you. We're quite happy with the Chinese label. And I think it's worth noting, because during my career I can't remember a new class of medicines ever getting approved in China first. So that's really something to keep in mind. So we're waiting on the FDA label. We haven't hit the PDUFA date yet. So there's still a bit of time remaining. And right now, whether it will be the same label is speculative. I think you described it correctly. The Chinese label is very solid, with no significant restrictions that I could see. So we're in intensive discussions with the FDA, and let's see what comes out of them. As for what this means relative to milvexian, I think it's not very helpful to speculate too much at this point. Obviously, we believe we have an extremely solid data set when it comes to secondary stroke prevention, where I think whoever gets there will have to come up with something really, really good if they want to beat us. So we feel very strong that we also most likely have about a year's advantage over the second follow-up. And then I think that will help us. And we'll have to see about milvexian.

Stefan Oelrich

executive
#28

They've got several studies underway, as you're aware, for several indications, as you're aware. So at this stage, I'd say it's purely speculative.

William Anderson

executive
#29

Okay, and yes — thank you, Stefan, and it's really nice to see you, or at least to hear your voice. On the judge's ruling about the settlement: we expect — well, we had expected a decision before Christmas, as we said, so it's arriving shortly. It ought to land within the coming several weeks. Then, on the opt-out question, let me walk through how the process works a bit. An opt-out deadline fell in early June — that was the window when individuals could choose to opt out. This is somewhat unusual, though, because 3 developments have occurred since then. The first was the Supreme Court ruling, which came down strongly on our side. The second was the fairness hearing, which in our view went quite well. And the third was the trial that took place, or that was read out last week — the first trial testing these other sorts of legal theories, and it produced a unanimous defense verdict. So as you can imagine, a fair number of plaintiffs and plaintiffs' councils opted out in early June but might revisit that choice given what has happened since.

William Anderson

executive
#30

And that is actually true, and those lawyers and plaintiffs are showing quite a bit of interest. There's a mechanism for getting into the class, and it's moving along at a fairly quick pace. But there is some administrative burden involved in opting out. Getting back in also carries an administrative burden, and it's subject to approval from Class Counsel and from us as well. Now, when the judge rules, there will be some declaration of how many opt-outs there are. But keep in mind that after that date, if there are existing opt-out requests still in process or new ones arriving, those can still be permitted back into the class, again subject to approval by class counsel, the company, and the judge. So whatever that number turns out to be will probably be a moving number, because it's on its way down, and it will likely keep going down. So hopefully that helps you a little in deciphering it.

Jana Ackermann

executive
#31

Following that, we have James Quigley from Goldman Sachs.

James Quigley

analyst
#32

I have 2 questions on pharma, so 2 please, Stefan. First, regarding Kerendia, was I right in hearing that full-year growth is expected to be 60%, 6-0 percent? We saw 76% in the first 9 months, which implies a sequential decline in both absolute revenues and growth. So are there any headwinds, et cetera, that we should factor in when modeling the full year? And then an update on how the launch is progressing across the 3 -- across the 2 different indications -- indications, sorry, and also the geographical rollout, that would be great. Second, to follow up on Richard's question about Nubeqa and IRA. Obviously, with the drug now annualizing at about EUR 4 billion, what does that mean for the potential for IRA negotiation? What is your base case for when you could see -- when you could be included in the negotiations? And do you have any sense, based on what you've seen so far with other drugs, of what the potential price hit could be and the impact on growth?

Stefan Oelrich

executive
#33

Thanks, James. So with Kerendia, because the base keeps expanding, the percentage growth will decline somewhat in Q4. All the same, momentum remains positive across both indications. And we are mostly a non-Europe play, which is unfortunate given the very low pricing we have in Europe. So as we look at the full-year picture, there may be some rebate considerations we need to add. That's the reason we've taken this 60% choice, but it's a really good question. On Nubeqa and IRA negotiations, we expect to get started in '27. So we will have an impact of IRA sales starting as of '28. And so it's coming. And we'll have to see whether we can negotiate at price levels similar to what competition has. And it certainly is a clear headwind going forward.

Jana Ackermann

executive
#34

Our following question is from Charles Pitman at Barclays.

Charles Pitman

analyst
#35

Two questions, if I may. First, on pharma margins: could you provide a bit more detail on the 3Q dynamics and how we should interpret these going forward, keeping in mind the expected investment in preparing for an milvexian launch? So I'm just thinking about whether the 3Q gross margin and SG&A and R&D levels are suitable weathers going forward, and also on D&A, noting that it crept up in the quarter. And then second, for Judith, thinking about the dividend and noting that B has been paying EUR 0.11 per share since '23, but litigation remaining on track. How can we think about the capital allocation decision framework for FY '26, '27 dividends?

William Anderson

executive
#36

Stefan, would you like to say something about how margins are trending?

Stefan Oelrich

executive
#37

Yes. Thank you for that question. So before I address it, I need to fix something I said a moment ago in my reply to James on the earlier question. I stated that '28 and unmet '29 represents the effect of the IRA negotiations. I have to correct myself on that. Now, regarding pharma margins this quarter, we had several pluses and minuses, including some divestitures, and those pushed the margin higher. So when you look at that very strong Q3 margin, you likely need to subtract roughly 20 basis points to arrive at our true operational level, which remains a meaningful improvement tied to our robust growth in the third quarter. On the other side, you will see additional sales expenditures coming onstream in the quarters ahead, increasingly from the asundexian launch — or I should say now the Sunharbo launch. That effort will begin with the first quarter in the U.S. and hopefully, and certainly, in China. So that will put pressure on the margin. As a result, our term guidance is unchanged, and it is what we shared with you at the start of this year: for the coming year we foresee a stable outlook, perhaps even slightly greater margin pressure owing to the investments, and then gradual margin improvement toward 30% in the years that follow, through 2030.

Judith Hartmann

executive
#38

Charles, turning to the dividend and how we allocate capital: it's a bit early to discuss '27 and past that, though I can share my thinking and the way I approach it. Really, given the results we just walked through, we do anticipate having more cash coming in across the years ahead. Crop Science is at work on the 5-year plan. You've just heard about the amazing success in pharma. Consumer Health has a very solid base of close to EUR 1 billion of cash flow and, with the litigation containment Bill mentioned, we should see lower outflows. So really, I'm confident we'll be able to accomplish several things. We'll be able to substantially raise our investment into the future. We will be able to pay down debt. And yes, of course, in time, we will also begin paying a higher dividend again.

Jana Ackermann

executive
#39

Vincent Andrews with Morgan Stanley is up next.

Vincent Andrews

analyst
#40

Rodrigo, a quick question. To start, corn prices have been somewhat volatile since summer ended. Could you discuss how that's been affecting the order book for the North American 2027 season? And then, second, in Crop Protection, results look sequentially softer than what you'd expected from 2Q to 3Q. Is that again the case from 3Q to 4Q? And as part of that, could you address what's going on with raw material costs in Crop Protection — whether that's getting worse and what you're able to do about it?

Rodrigo Santos

executive
#41

Thanks a lot, Vincent. I'll begin with U.S. corn. You saw that area came down this year, but we'll likely finish at roughly 97 million acres in the U.S., which was somewhat above what the market had anticipated. Looking at next year, based on what we see today — and again, plenty is developing right now, and we'll learn more over the coming weeks and months — potentially we're looking at a decline toward something nearer the historical level for U.S. corn area. That's roughly what we're observing — our order book is strong, since we're also launching many new-generation hybrids into the market and the package we have is strong, yet as of now we expect a lower area next year, and we're going to need to land close to that number. On CP, on Crop Protection, for the full year, we of course factored in the effect of the regulatory and product exits that Judith mentioned in the script here, and that accounted for a big part of it.

Rodrigo Santos

executive
#42

My take on Q3 is that weather was the driver, correct? In particular, the dry spell and the heat during the season across Europe and Asia hit our fungicide applications and our herbicide side. That's the effect we saw in Q3. Now we're moving into Latin America, where we're putting up strong performance. As you're aware, our portfolio there is very strong on the fungi side with Fox Supra and Fox Ultra, along with Luna. So on the fungi side we had a very strong portfolio. On insecticide too, we had the <<inaudible>> Prime expansion. So LatAm is performing well in Q4, and we're hoping for that to hold for the full year as well. But the core element in Q3 worth calling out, I think, was the weather impact. That's probably the single piece, and we're managing our portfolio and our platforms here to deliver. Which is why we're very confident about delivering the guidance for '26. So thank you for your questions.

Jana Ackermann

executive
#43

And our following question is from Matthew Weston at UBS.

Matthew Weston

analyst
#44

I have a couple of questions about asundexian and how the launch trajectory looks, Stefan, if that's alright. Obviously, expectations are high across the board. I'm sure yours are as well. That said, could you help us put some framing around a few of these points? What split would you expect between Medicare, Medicaid, and commercial in the U.S.? And beyond that, really just help us frame how the first year should be viewed. Should we anticipate a substantial period of free drug and bridging programs at the start of the launch? Or do you feel confident that we'll see some meaningful revenue ramp with commercial access coming relatively early?

Stefan Oelrich

executive
#45

That's an excellent question, Matthew. It's one I'm putting to my own team too. And we can't give a definitive answer, since there aren't many precedents we can point to. What this means is that the indication will most likely be heavily protocolized. In acute cases, then, our expectation is that patients will go home with a 1-month supply. I believe that will place considerable pressure on payers to continue these prescriptions. So that argues for a good uptick dynamic. But we'll really have to wait and see what the label says, because my sense is the label will tell us whether payers may introduce any limitations, or whether they won't — at this stage, it's genuinely speculative. Turning to Medicare, this is clearly a population with a high level of patients covered through Medicare, so Medicare will be important, and as you know, we face some limitations regarding our promotional penetration in Medicare. As for commercial plans, we're going to give patients very strong support early on, so that they can keep up the treatment after they're discharged from the hospital.

Stefan Oelrich

executive
#46

On Medicaid, there’s nothing further we can add right now. Still, my sense is we’ll simply need to watch how things develop. Our efforts have to center on the hospital first, so we can move into that protocolized setting as quickly as possible, which lets patients leave with the appropriate treatment grounded in our very strong data set.

Operator

operator
#47

Next up, we have Joe Jackson from BMO, who's on the line.

Joel Jackson

analyst
#48

I’ll ask 2 questions one at a time, if that’s all right. For the first one — and Rodrigo may be the right person — Bill, across the Crop Protection industry there’s been talk about rebates, particularly in the U.S., with rebate models shifting and gross-to-net spreads. Could you describe what’s going on in CP from the perspective of Bayer’s business — the gross-to-net spreads, pricing, how that has changed, and how you’ve adapted?

Rodrigo Santos

executive
#49

Yes, Joe, I will — thank you for asking. And let me take this chance here. I didn't bring it up earlier, Vincent, but you also asked about how raw materials are affecting us, correct? So yes, there is an effect, though we're handling it through the steps we're taking, including on sourcing and renegotiating certain items that were brought up as well. I just wanted to flag that point. On the CP side, Joe, to dig a bit further. Our plan is very clear. For many years now, we've run sellout and selling for our crop protection with a lot of discipline around pricing, inventories in the channel, and gross to net. So our gross-to-net approach differs by product and by region. As a result, we aren't seeing anything significant shift. These are simply products that are required because of generics, but on that front there's no major change for us at the moment. So we continually adjust our plans and respond to the market, yet on that item there's no massive impact for us. And what was your second question?

Joel Jackson

analyst
#50

Yes. For my second question — and I believe this one is for Bill — what have we learned? What lessons have you taken from the separation of <<inaudible>> during the past month? I mean, you've been — I'm certain, Bill, that every single day in this role, having held this job, people have put the question to you: will you ever spin off Crop Science at some point? What have you picked up from observing that operation? And if you reached a greater level of comfort and, looking at the portfolio further out, you were perhaps to decide to break up Crop Science, might you consider splitting it into 2 parts, with seeds and crop chems separated? Or what lessons has that experience over the last month of <<inaudible>> given you?

William Anderson

executive
#51

Yes, Joel, thanks for that question. I'd also like to hear what Rodrigo thinks, since he's clearly the person nearest to the crop science business. That said, my first point would be that we're only 1 month in, so I'm not sure much can be learned at this stage. Time, I think, will be a more important factor when it comes to genuinely assessing how that plays out. And for us, what mainly keeps us focused on what we're doing right now — which is really still pushing hard on our 5 key opportunities, but also going all out with AI implementation across Bayer — is just the opportunity cost of sort of structural adventures. Because when I think about the 88,000 people of Bayer and how hard they've been working to drive these kinds of results, like the asundexian, getting asundexian into market a year before our competitor has their Phase III data — that doesn't happen just sort of on its own. That's about people being laser-focused on the business, on the operations, on simplifying every process, and we've taken out almost 70% of management in the last 3 years. We've put a whole new way of operating in.

William Anderson

executive
#52

That isn’t something MB can do with that type of company division. So we appreciate the focus we’ve got. We believe it’s producing stronger results. And I think I can say for everyone here that we don’t believe we’re anywhere near finished with this, in terms of the improvements we can still make when it comes to driving faster action, higher productivity, and better customer satisfaction. So that’s roughly our main thinking. We aren’t especially focused on the competitors. Our focus is on beating ourselves and delivering a better result each quarter. So that’s probably our main outlook. But Rodrigo, perhaps you have some specific insights on the crop science field and how that is shaping up?

Rodrigo Santos

executive
#53

Let me just add to that, Joe — I think we covered a great deal of this in <<inaudible>>. From my perspective, it comes down to a lot of out performance and to driving performance across our business over the coming years. Within our industry, such performance is tightly linked to innovation and to the way we operate. What truly matters to us, then, is performing on every platform we have, just as we said. Let me offer a few examples from this year, which was referenced — I'm very pleased that we're on the seeds and traits platform, for instance, where we sit at 12% year-to-date performance. Even leaving out the licensing resolution, it stands at 5.4%, which means 4% in corn, 10% in soybean year-to-date, 16% on cotton, 25% on the other seeds and traits, particularly in canola. So we have to perform on core protection. Compared with the market, and compared with the competitors that have already reported, the discipline with which we execute our crop protection is very important. This year we plan to moderate sales owing to the margin expansion focus we have. So we account for the regulatory and the product assets. As I mentioned, weather was probably a bigger impact, but that's how we manage egg, right?

Rodrigo Santos

executive
#54

This is pretty standard for how we operate. So the thing I keep coming back to is performance. That's where the organization is focused. It's very clear — the whole organization is tightly aligned around our 5-year framework and how we carry that forward over the next year. So that's the objective we have to pursue: driving innovation growth, margin expansion and cash generation, and that's exactly what we'll keep doing.

Jana Ackermann

executive
#55

We’ve got 3 more queued up. Up next is Christian Faitz with Kepler Cheuvreux.

Christian Faitz

analyst
#56

I have a couple of questions, if I may. The first is about Crop Science. Are you observing channel inventories tied to weather that might be a drag on '27 for Crop Protection products — in Europe in particular, I suppose — or are you already addressing that this year by buying back some of those volumes? And the second: regarding the settlement timing context, and given that we are already well into Q4, would you still anticipate that a significant share of the flat EUR 5 billion cash outflow occurs this year?

Rodrigo Santos

executive
#57

Thanks, Christian. Regarding inventory — as I mentioned, we are extremely disciplined when it comes to managing sellout and selling. The moment we detect any effect on sellout where there's a market impact, we cut our sales and manage inventory accordingly, and that's our approach globally. So we don't view it any differently. Naturally, when a weather event occurs like the one in Europe, you might end up with a particular country or application where you have a bit of what you'd anticipated from a new cite application, and conditions are so dry that it doesn't happen — but we manage that too. So we don't see a massive inventory problem. I believe we're keeping it at the right level, maintaining low inventory in the channel so the business can be run the way it should be. I think we're on track there. Bill?

William Anderson

executive
#58

I believe Judith will handle that one.

Judith Hartmann

executive
#59

Yes. Regarding those settlement payments, we had mentioned EUR 5 billion for this year. I'd say we're roughly 60-ish percent through that, so as of now we're keeping it as our forecast — though there's certainly a chance that part of it slips into next year.

Jana Ackermann

executive
#60

Moving on, we have Thibault Boutherin from Morgan Stanley.

Thibault Boutherin

analyst
#61

Turning to the pharma tariff question — the effect is modest for this year, but how should we frame next year and the margin? You announced a sizable investment in U.S. manufacturing. Can you confirm that talks with the administration are also continuing in that context? And just to clarify, you brought up how MFN affects pricing and strategy. I want to confirm that these considerations relate to actually reaching an agreement. So, since no deal exists right now, do launch and pricing remain constrained for you?

Stefan Oelrich

executive
#62

Yes, I’ll take that. Thibault, thank you. Now, regarding both tariffs and — let me begin with the Ohio investment. The Ohio investment is clearly a sign that our strategy of renewed focus on the U.S. market is really coming through. That also includes bringing manufacturing to where our biggest markets are in the world we live in now. So I think it makes all the sense in the world. That’s one thing. The second one concerns MFN and tariffs going forward. So a point, I’m not in a position to give you a precise pinpointed guidance. These are ongoing discussions, you’re right. We’re one of the companies that has not signed a deal on this. So right now, that would mean we would be exposed to potential tariff impact and potential garden globe impact. And this is something that we’re currently discussing still. So stay tuned. You will get an update with the first quarter and our guidance for next year.

Jana Ackermann

executive
#63

Alright, I believe we have 2 additional questioners at this point. So up next is Rajesh Kumar from HSBC, and after that we have more before wrapping up. Rajesh, the floor is yours.

Rajesh Kumar

analyst
#64

To start, I want to clarify the cost base and run rate. I understand the quarter contained several technical items—inventory movements, possibly some litigation gains from discount rate changes, the nonstrategic brand sale, and so on. Because of that, it's somewhat hard to determine the run rate cost base from SG&A. If you could help us on a run rate basis with how you expect the cost base to trend into '27, that would be very helpful, particularly since taking the third quarter run rate and extrapolating it to '27 would have you beginning to see margin expansion in pharmaceutical, which appears to conflict with what you may be indicating. So that's my clarification question. And the second one: I know you clearly don't want to speculate about what mill vaccine competition in SSP might do to index and uptake and <<inaudible>>. But if we were to think through the scenarios—one in which mill vaccine succeeds is comparable to what we saw with asundexian, it could fail in SSP, or it could do better. And that data will come this year. The SSP comes out next year.

Rajesh Kumar

analyst
#65

On the scenario where SSP is either a hit or a miss, or perhaps relative to where you stand, how do you think that would affect or help your uptick in pricing discussions and so forth? If you could address those scenarios — I'm 100% certain that, like everybody else, you don't have the answer either. So just hearing how you're approaching the problem would be really helpful.

William Anderson

executive
#66

Stefan, on that first question — maybe it wasn't entirely clear — but I believe what you're getting at, Rajesh, is the pharma margin in Q3, correct?

Rajesh Kumar

analyst
#67

Yes.

William Anderson

executive
#68

Right. So — and just to put it in other words, Stefan, I believe you were making the point that people shouldn't read too much into the Q3 margin, since the larger outlay on asundexian hasn't started to show up yet. And a few other items were somewhat uneven. So I think you probably need to lean more on the longer-term guidance Stefan has been giving, instead of zeroing in on Q3 and treating it as a new normal. Is that a fair way to put it, Stefan?

Stefan Oelrich

executive
#69

Yes. That is precisely what I stated earlier. I mean, clearly we're quite pleased to observe the margin getting better as a result of growth. But once more, a portion of the significant costs — extra expenses — have not yet arrived and will come next year, and that will more or less balance things out to some extent, or perhaps even tip the scales beyond that. We likewise had R&D spending that was comparatively low in Q3. Don't count on it remaining at that same level. So there are both pluses and minuses. So I believe the guidance we gave before still holds. And regarding asundexian, let's make 2 things clear. First, we have — somebody said to me at an investor meeting the other day that this is an uncommon data set in cardiology. So I think at times we fail to give ourselves sufficient credit for just how strong our data set truly is; a 26% reduction in secondary stroke with no additional important bleeds is something that caught everyone off guard. So a competitor needs to beat that or at minimum match it. So I feel highly confident about this data set. Second, we hold first-mover advantage. And let's not downplay this. We are strong in cardiology. We've been steadily building our cardiology footprint in the United States across the last few years, and our performance on Kerendia, which, incidentally, over moving 12 months has already gone past the EUR 1 billion level.

Stefan Oelrich

executive
#70

You know, as a reminder, a lot of folks saw this as being at its peak — a considerably smaller product. So we've demonstrated our marketing capabilities, and we're strong on that front as well. So it's not that we'll just be relying on our label in China. We're strong regardless. And for Europe, we'll need to see how it shakes out. And whether asundexian has both products, both edification, one indication — I think what matters to us is our own strength. And I'm not — and I'm also telling our teams: don't spend so much time looking in the rearview mirror at who might be coming in there; instead, look forward. So we're going to keep building on the strong differentiation we already have at this point. We're establishing a new standard of care in stroke — secondary stroke prevention. And so we feel very good. Maybe a final word on margin. I understand that you're all asking this because it's clear that Pharma has turned a corner and that we're emerging from the — what we call the resilience phase, and we're now in growth. So expect continued growth in the quarters to come. There will be — sequentially, sometimes some months, but I think with that guidance that we've given, we can expect it to clearly hold.

Stefan Oelrich

executive
#71

Ideally, we'd like to grow at mid-single digits—above that, of course—but mid-single digits over the next few years through 2030, and margin improvement beginning in '27.

Jana Ackermann

executive
#72

And our final question this session is from Tony Jones at Redburn.

Tony Jones

analyst
#73

I have a couple of questions, and I'll keep them brief. The first is for Rodrigo: can you confirm that technology licensing income remains at roughly EUR 2 billion, leaving out the Corteva agreement? Also, should we expect any pluses or minuses affecting that figure in 2027? Then a quick second one for Judith regarding cash: do you anticipate any meaningful growth CapEx in '27 and '28, or growth investments, or any other cash costs that could affect free cash flow?

Rodrigo Santos

executive
#74

Tony, let me take your question. The license resolution in Q1 of this year came to EUR 450 million. As you mentioned, our lifesaving business overall is above EUR 2 billion, and that's accurate. The majority of it rests on small and regional companies. And with the new launches we have — <<inaudible>> Biotech, <<inaudible>> — we're projecting, across our 5-year framework, that we'll keep pursuing the licensing strategy to grow that business. So the number you have there is right.

Judith Hartmann

executive
#75

Then, Tony, regarding investments for years ahead: what I'd say is that we need to earn the money first before we begin putting it in. But as I mentioned earlier, we're quite positive when we look at these results and at what they mean going forward, in the sense that profits will bring higher cash flows. We're also working on measures related to trade working capital. So we'll return in '27 with renal projected investments for that year. But as time goes on, we're confident that investments will rise.

Jana Ackermann

executive
#76

We appreciate your questions and your interest. That brings our Q3 2026 earnings call to a close. Have a great day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Bayer Aktiengesellschaft transcript — plus 133,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Bayer Aktiengesellschaft earnings transcripts and 133,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Bayer Aktiengesellschaft or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.